252 related articles for article (PubMed ID: 35551301)
1. Preclinical and clinical developments for combination treatment of influenza.
Koszalka P; Subbarao K; Baz M
PLoS Pathog; 2022 May; 18(5):e1010481. PubMed ID: 35551301
[TBL] [Abstract][Full Text] [Related]
2. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.
Kumar D; Ison MG; Mira JP; Welte T; Hwan Ha J; Hui DS; Zhong N; Saito T; Katugampola L; Collinson N; Williams S; Wildum S; Ackrill A; Clinch B; Lee N
Lancet Infect Dis; 2022 May; 22(5):718-730. PubMed ID: 35085510
[TBL] [Abstract][Full Text] [Related]
3. Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir.
Salvatore M; Laplante JM; Soave R; Orfali N; Plate M; van Besien K; St George K
Transpl Infect Dis; 2020 Aug; 22(4):e13336. PubMed ID: 32449254
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report.
Harada N; Shibata W; Koh H; Takashita E; Fujisaki S; Okamura H; Nanno S; Yamada K; Nakamae H; Hino M; Kakeya H
BMC Infect Dis; 2020 Jul; 20(1):478. PubMed ID: 32631240
[TBL] [Abstract][Full Text] [Related]
6. Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients.
Macesic N; Laplante JM; Aaron JG; DiMango EA; Miko BA; Pereira MR; Reshef R; St George K
Transpl Infect Dis; 2021 Jun; 23(3):e13542. PubMed ID: 33278052
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
Fukao K; Noshi T; Yamamoto A; Kitano M; Ando Y; Noda T; Baba K; Matsumoto K; Higuchi N; Ikeda M; Shishido T; Naito A
J Antimicrob Chemother; 2019 Mar; 74(3):654-662. PubMed ID: 30476172
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Drugs in Influenza.
Świerczyńska M; Mirowska-Guzel DM; Pindelska E
Int J Environ Res Public Health; 2022 Mar; 19(5):. PubMed ID: 35270708
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis.
Liu JW; Lin SH; Wang LC; Chiu HY; Lee JA
JAMA Netw Open; 2021 Aug; 4(8):e2119151. PubMed ID: 34387680
[TBL] [Abstract][Full Text] [Related]
10. Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy.
Zambon M
Curr Opin Infect Dis; 2014 Dec; 27(6):560-5. PubMed ID: 25333476
[TBL] [Abstract][Full Text] [Related]
11. Influenza virus resistance to neuraminidase inhibitors.
Samson M; Pizzorno A; Abed Y; Boivin G
Antiviral Res; 2013 May; 98(2):174-85. PubMed ID: 23523943
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
Komeda T; Takazono T; Hosogaya N; Ogura E; Fujiwara M; Miyauchi H; Ajisawa Y; Iwata S; Watanabe H; Honda K; Kitanishi Y; Hara K; Mukae H
Clin Infect Dis; 2021 Jun; 72(11):e859-e867. PubMed ID: 33103200
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
Komeda T; Takazono T; Hosogaya N; Miyazaki T; Ogura E; Iwata S; Miyauchi H; Honda K; Fujiwara M; Ajisawa Y; Watanabe H; Kitanishi Y; Hara K; Mukae H
Clin Infect Dis; 2021 Sep; 73(5):e1181-e1190. PubMed ID: 33354728
[TBL] [Abstract][Full Text] [Related]
14. Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir.
Tilmanis D; Koszalka P; Barr IG; Rossignol JF; Mifsud E; Hurt AC
Antiviral Res; 2020 Aug; 180():104851. PubMed ID: 32544408
[TBL] [Abstract][Full Text] [Related]
15. Neuraminidase inhibitor resistance in influenza viruses.
Reece PA
J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
Checkmahomed L; Padey B; Pizzorno A; Terrier O; Rosa-Calatrava M; Abed Y; Baz M; Boivin G
Viruses; 2020 Oct; 12(10):. PubMed ID: 33049959
[TBL] [Abstract][Full Text] [Related]
17. Influenza and antiviral resistance: an overview.
Lampejo T
Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1201-1208. PubMed ID: 32056049
[TBL] [Abstract][Full Text] [Related]
18. Neuraminidase inhibitors for preventing and treating influenza in children.
Matheson NJ; Symmonds-Abrahams M; Sheikh A; Shepperd S; Harnden A
Cochrane Database Syst Rev; 2003; (3):CD002744. PubMed ID: 12917931
[TBL] [Abstract][Full Text] [Related]
19. Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza.
Abraham GM; Morton JB; Saravolatz LD
Clin Infect Dis; 2020 Oct; 71(7):1790-1794. PubMed ID: 32020174
[TBL] [Abstract][Full Text] [Related]
20. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020.
Govorkova EA; Takashita E; Daniels RS; Fujisaki S; Presser LD; Patel MC; Huang W; Lackenby A; Nguyen HT; Pereyaslov D; Rattigan A; Brown SK; Samaan M; Subbarao K; Wong S; Wang D; Webby RJ; Yen HL; Zhang W; Meijer A; Gubareva LV
Antiviral Res; 2022 Apr; 200():105281. PubMed ID: 35292289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
